Long-term effects of netakimab on health-related quality of life, back pain and work productivity in patients with ankylosing spondylitis: results of the international, multicentre, randomized double-blind phase III clinical trial BCD-085-5/ASTERA
Authors:
- T. V. DubininaTDT. V. Dubinina
- A. B. DeminaADA. B. Demina
- E. M. AgafonovaEAE. M. Agafonova
- Sh. F. ErdesSESh. F. Erdes
- V. I. MazurovVMV. I. Mazurov
- I. Z. GaydukovaIGI. Z. Gaydukova
- A. M. PristromAPA. M. Pristrom
- E. V. KunderEKE. V. Kunder
- N. F. SorokaNSN. F. Soroka
- A. A. KastanayanAKA. A. Kastanayan
- T. V. PovarovaTPT. V. Povarova
- E. S. ZhugrovaEZE. S. Zhugrova
Open Access
- 19 December 2023
- journal article
- research article
- Published by IMA Press, LLC in Modern Rheumatology Journal
- Vol. 17 (6) , 52-58
Abstract
The article contains the data obtained during the 156-week follow-up of patients with ankylosing spondylitis (AS) in the ASTERA phase III study.Objective: to evaluate the effect impact of netakimab (NTK) on quality of life (QoL), back pain and work capacity in patients with active AS.Material and methods. The study enrolled 228 patients with active AS who were randomized 1:1 to receive NTK 120 mg or placebo. At week 52, patients in Group 1 (NTK) who achieved ASAS20 continued therapy (NTK at a dose of 120 mg once every 2 weeks) until week 156. Patients in Group 2 (placebo/NTK) received the study drug at a dose of 120 mg subcutaneously every 2 weeks from week 20 until week 68, after which the efficacy of therapy was determined (by achieving an ASAS20 response). Patients who achieved ASAS20 received treatment (NTK at a dose of 120 mg once every 2 weeks) until week 172.Results and discussion. Under NTK therapy, a significant improvement in QoL was observed in the assessment of the physical and psychological components of the SF-36 questionnaire, which was maintained during the three years of therapy: increase in indicator by 12.68±9.92; 13.27±10.14; 12.92±10.03; 14.10±10.35; 14.76±9.77 and 6.10±11.59; 5.50±11.82; 6.32±11.01; 5.87±11.45; 5.25±11.98 points at week 52, 76, 104, 128 and 156, respectively. During the extended therapy period, a reduction in the proportion of working hours missed for health reasons, an improvement in work capacity and work efficiency and an increase in daily activity were observed. Back pain (BASDAI question 2) and nocturnal back pain decreased steadily during the entire follow-up period compared to the screening values.Conclusion. NTK is an effective therapy for active AS that improves QoL scores, significantly reduces pain intensity and improves work productivity.Keywords
This publication has 16 references indexed in Scilit:
- The effect of intravenous golimumab on health-related quality of life and work productivity in adult patients with active ankylosing spondylitis: results of the phase 3 GO-ALIVE trialClinical Rheumatology, 2020
- Efficacy and safety of netakimab, anti-IL-17A monoclonal antibody, in patients with ankylosing spondylitis. Results of phase III international, multicenter, randomized double-blind clinical trial BCD-085-5/ASTERARheumatology Science and Practice, 2020
- Secukinumab shows sustained efficacy and low structural progression in ankylosing spondylitis: 4-year results from the MEASURE 1 studyRheumatology, 2018
- Effect of Secukinumab on Patient‐Reported Outcomes in Patients With Active Ankylosing Spondylitis: A Phase III Randomized Trial (MEASURE 1)Arthritis & Rheumatology, 2016
- Health-related quality of life in patients with ankylosing spondylitis: a comprehensive reviewExpert Review of Pharmacoeconomics & Outcomes Research, 2014
- Pain is a major component of quality of life in patients with ankylosing spondylitis and the possibilities of its reliefModern Rheumatology Journal, 2013
- The World Health Organization's WHOQOL-BREF quality of life assessment: Psychometric properties and results of the international field trial. A Report from the WHOQOL GroupQuality of Life Research, 2004
- Ankylosing spondylitis assessment group preliminary definition of short-term improvement in ankylosing spondylitisArthritis & Rheumatism, 2001
- The Validity and Reproducibility of a Work Productivity and Activity Impairment InstrumentPharmacoEconomics, 1993
- Validating the SF-36 health survey questionnaire: new outcome measure for primary care.BMJ, 1992